Floatz logo

Cediranib

Rectal Signet Ring Cell Adenocarcinoma

Wake Forest University Health SciencesSmall moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Rectal Signet Ring Cell Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
mk-2206
National Cancer Institute (NCI)
Phase 2CCC
Capecitabine
M.D. Anderson Cancer Center
Phase 2CCC
Cetuximab
National Cancer Institute (NCI)
Phase 1CCC
rg4733
National Cancer Institute (NCI)
Phase 1C

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →